News

Biotech Dispatch
biotechdispatch. com. au > news > immutep-reassesses-and-resets-lead-cancer-program-following-trial-setback

Immutep reassesses and resets lead cancer program following trial setback

13+ hour, 49+ min ago  (218+ words) Immutep (ASX: IMM) recently announced the discontinuation of its Phase 3 TACTI-004 study in first-line non-small cell lung cancer, following an interim futility analysis that showed patients receiving its lead candidate underperformed the control arm. The decision, guided by the Independent Data…...

Biotech Dispatch
biotechdispatch. com. au > news > vitura-health-names-justin-james-as-ceo-to-drive-next-phase-of-growth

Vitura Health names Justin James as CEO to drive next phase of growth

2+ day, 14+ hour ago  (316+ words) Vitura Health (ASX: VIT) has appointed experienced healthcare executive Justin James as its new chief executive officer, marking a significant leadership shift as the company positions itself for further expansion in emerging therapies and digital health services. The Melbourne-based company…...

Google News
biotechdispatch. com. au > news > clinuvel-spotlights-vitiligo-progress-and-long-term-safety-data-at-major-dermatology-gathering

Google News

2+ day, 14+ hour ago  (14+ words) Clinuvel spotlights vitiligo progress and long term safety data at major dermatology gathering'Biotech Dispatch...

Biotech Dispatch
biotechdispatch. com. au > news > amplia-therapeutics-amplicity-clinical-trial-recruitment

Amplia Therapeutics halts AMPLICITY clinical trial recruitment

2+ day, 14+ hour ago  (139+ words) Amplia Therapeutics (ASX: ATX) has halted recruitment to its AMPLICITY clinical trial. The Melbourne-based company had been studying narmafotinib in combination with the widely used but aggressive m FOLFIRINOX regimen in patients with advanced pancreatic cancer. After eight patients were…...

Biotech Dispatch
biotechdispatch. com. au > news > csl-navigates-new-us-pharmaceutical-tariff-plan-and-expects-limited-impact

CSL navigates new US pharmaceutical tariff plan and expects limited impact

2+ day, 14+ hour ago  (251+ words) Biotech Dispatch CSL navigates new US pharmaceutical tariff plan and expects limited impact CSL (ASX: CSL) has responded cautiously to the United States Administration's announcement on 2 April 2026 outlining its intention to introduce tariffs on imported pharmaceutical products under Section 232 of…...

Biotech Dispatch
biotechdispatch. com. au > news > algorae-pharmaceuticals-secures-fresh-capital-to-accelerate-ai-driven-drug-strategy

Algorae Pharmaceuticals secures fresh capital to accelerate AI driven drug strategy

2+ day, 14+ hour ago  (230+ words) Algorae Pharmaceuticals (ASX: 1 AI) has moved to strengthen its financial footing, announcing a $3. 9 million capital raise to scale its commercial operations and advance its artificial intelligence-driven research pipeline. The company confirmed it had "successfully raised $3, 988, 183 (before costs)," drawing funds from…...

Biotech Dispatch
biotechdispatch. com. au > news > telix-strengthens-board-with-seasoned-life-sciences-executive-as-leadership-transition-takes-sha

Telix strengthens board with life sciences executive as leadership transition takes shape

1+ week, 14+ hour ago  (209+ words) Telix Pharmaceuticals (ASX: TLX) has moved to bolster its board and leadership succession plans with the appointment of veteran healthcare executive David Gill as a non-executive director. The Melbourne-headquartered radiopharmaceutical company announced that Gill will join the board effective May…...

biotechdispatch. com. au
biotechdispatch. com. au > news > engineered-immune-cells-show-striking-durability-against-hard-to-treat-cancers

Engineered immune cells show striking durability against hard to treat cancers

1+ week, 15+ hour ago  (317+ words) Arovella Therapeutics (ASX: ALA) has reported new preclinical data that strengthens the case for its engineered immune cell platform, demonstrating sustained and enhanced killing of pancreatic and gastric cancer cells in laboratory studies. At the centre of the work is…...

Biotech Dispatch
biotechdispatch. com. au > news > ai-meets-oncology-as-algorae-advances-drug-discovery-collaboration

AI meets oncology as Algorae advances drug discovery collaboration

1+ week, 2+ day ago  (244+ words) Algorae Pharmaceuticals (ASX: 1 AI) has taken another step in its push to transform drug discovery through artificial intelligence, deepening its collaboration with the Peter Mac Callum Cancer Centre in a new program aimed at validating AI-predicted drug combinations. The agreement…...

Biotech Dispatch
biotechdispatch. com. au > news > aroa-biosurgery-reports-promising-trial-milestone-for-advanced-wound-treatment

Aroa Biosurgery reports promising trial milestone for advanced wound treatment

1+ week, 2+ day ago  (200+ words) Aroa Biosurgery (ASX: ARX) has announced the completion of a significant clinical trial that it says could shape the future of chronic wound care. The Auckland-based regenerative medicine company has finished its Symphony randomised controlled trial, a multi-centre study focused…...